Ocugen and Bharat Biotech Say Shot Neutralizes Delta and Omicron
Excerpt from the Press Release:
On Wednesday, partners Ocugen and Bharat Biotech said data from the preliminary analysis of the Covaxin booster shot had been found to neutralize both Omicron and Delta variants of SARS-CoV-2 successfully.
Ocugen Inc., a biopharmaceutical company developing gene therapies to cure blindness diseases and a vaccine to save lives from COVID-19, and partner Bharat Biotech, a multidimensional biotechnology company making vaccines and biotherapeutics, announced promising results of the Covaxin (BBV152) study conducted at the Emory Vaccine Center.
The study conducted using a live virus neutralization assay showed the booster dose generated robust neutralizing antibody responses against both Omicron and Delta variants. Earlier trials have indicated the neutralizing potential of Covaxin against SARS-CoV-2 variants of concern Alpha, Beta, Delta, Zeta, and Kappa.
The analysis demonstrated blood serum collected from the Phase II study subjects who received Covaxin booster shots six months after getting a primary two-dose series of Covaxin neutralized both Omicron and Delta variants. One hundred percent of test serum samples showed neutralization of the delta variant, and more than ninety percent of serum samples showed neutralization of the Omicron variant.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?